Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

NCT06511908 is registered in ClinicalTrials.gov with National Institute of Mental Health (NIMH) as lead sponsor.

NCT NCT06511908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06511908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Lead sponsor
National Institute of Mental Health (NIMH)
Phase
Phase 2
Overall status
Recruiting
Start date
November 6, 2024
Completion date
July 1, 2027
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

behavioral symptoms, depression, depressive disorder, depressive disorder, major, depressive disorder, treatment-resistant, excitatory amino acid agents, ketamine, mental disorders, molecular mechanisms of pharmacological action, mood disorders, neurotransmitter agents, physiological effects of drugs, suicide